Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
- Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox
- Collaborations further the development of an end-to-end offering to support Lonza’s bioconjugates customers in overcoming a range of development and manufacturing challenges
Basel, Switzerland, 17 January 2023 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, today announced two new collaborations with McSAF and Cristal Therapeutics to expand its bioconjugates offering.
The collaborations will enable the integration of two novel conjugation platforms, McSAF Inside® and CliCr®, into the Lonza Bioconjugation Toolbox. The Lonza Bioconjugation Toolbox comprises a range of tailored solutions for the technology selection, development and manufacturing of bioconjugates to advance the development of novel bioconjugate-based therapies.
Cristal Therapeutic CliCr® technology is a novel class of versatile and highly reactive bioorthogonal reagents that supports the straightforward and highly-efficient generation of a large range of bioconjugates. The CliCr® technology relies on metal-free click chemistry and provides improved yields and broad applicability compatible with biochemically-relevant reaction conditions.
McSAF Inside® Technology allows for the fast and efficient generation of homogeneous and stable antibody-drug conjugates (ADCs) from native antibodies. The technology relies on a set of unique reagents for the site-specific conjugation of a linker-payload to previously reduced interchain cysteines of a native antibody. Compared to conventional methods, McSAF Inside® produces ADCs of high purity and stability and can support novel bioconjugates, based on antibody fragments or other therapeutic proteins that contain an accessible disulfide bond.
Through the new agreements, Cristal Therapeutics and McSAF will gain access to Lonza’s integrated bioconjugates offering and will be able to leverage Lonza’s expertise in developing and manufacturing bioconjugates. At the same time, the collaborations build additional capabilities into Lonza’s service portfolio, furthering the development of an end-to-end bioconjugates offering that can support customers in overcoming a range of development and manufacturing challenges.
Iwan Bertholjotti, Senior Director Commercial Development, Bioconjugates, Lonza, commented: “CliCr® and McSAF Inside® are great additions to the Lonza Bioconjugation Toolbox, allowing us to extend our portfolio of technologies for drug developers involved in developing novel bioconjugates/ADCs. These collaborations are creating a unique industry network to facilitate the development of novel bioconjugates with potential to treat life-threatening diseases.”